No quarterly revenue total was found in DAMORA THERAPEUTICS, INC.'s SEC filings.
Damora Therapeutics, Inc. (DMRA) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Sep 30, 2026 it held $528.5 million in cash and investments and $1.1 million in total debt.
Revenue
—
Net income
$-31.99M
-921.1% vs year-ago quarter
Operating cash flow
$-17.23M
-558.8% vs year-ago quarter
Free cash flow
—
EPS
$-0.40
+83.1% vs year-ago quarter
Dividend per share
$0.00
Shares outstanding
61.90M
+4564.3% vs year-ago quarter
Net cash
$527.38M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DMRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1800315
- Former names
- Galecto, Inc. (until Mar 10, 2026); Galecto Inc. (until Oct 28, 2020)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$36.9M | -$35.0M | -$30.8M | -$201.7M | -$3.2M |
| Net income | -$32.0M | -$31.2M | -$27.8M | -$200.7M | -$3.1M |
| Diluted EPS | -$0.40 | -$0.39 | -$0.62 | -$135.76 | -$2.36 |
| Operating cash flow | -$17.2M | -$21.9M | -$20.6M | $566,000 | -$2.6M |
| Total assets | $532.6M | $543.6M | $535.4M | $260.5M | $10.7M |
| Total liabilities | $36.9M | $27.6M | $23.8M | $20.1M | $2.7M |
| Stockholders' equity | $495.8M | $516.1M | $511.6M | $239.0M | $6.7M |
| Cash and investments | $528.5M | $540.5M | $532.9M | $257.6M | $7.6M |
| Total debt | $1.1M | — | — | $68,000 | $72,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Jul 20, 2026 | Jul 16, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 17, 2026 | Apr 28, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Officer or director change
|
May 4, 2026 | Apr 28, 2026 |
All 353 Damora Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.